Phase I study of CC-90010, a reversible, oral BET inhibitor in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)

被引：3
|
作者：
Moreno, V. [1 ]
Brana, I. [2 ]
Sepulveda Sanchez, J. M. [3 ]
Vieito Villar, M. [4 ]
Hernandez Guerrero, T. [1 ]
Doger, B. [1 ]
Saavedra, O. [2 ]
Pinto, A. [5 ]
Carlo Stella, C. [6 ]
Italiano, A. [7 ]
Michot, J-M. [8 ]
Musuraca, G. [9 ]
Sarmiento, R. [10 ]
De Alvaro, J. [10 ]
Zuraek, M. [11 ]
Sanchez-Perez, T. [10 ]
Aronchik, I. [11 ]
Filvaroff, E. [11 ]
Hanna, B. [11 ]
Nikolova, Z. [10 ]
机构：
[1] Hosp Univ Fdn Jimenez Diaz, START Madrid FJD, Madrid, Spain
[2] Hosp Univ Vall dHebron, Barcelona, Spain
[3] Hosp Univ 12 Octubre, Madrid, Spain
[4] Hosp Univ Vall Hebron, Barcelona, La Coruna, Spain
[5] Ist Nazl Tumori IRCSS Fdn Pascale, Naples, Italy
[6] Humanitas Clin & Res Ctr, Humanitas Canc Ctr, Milan, Italy
[7] Ctr Reg Lutte Canc Bordeaux & Sud Ouest, Inst Bergonie, Bordeaux, France
[8] Inst Gustave Roussy, Dept Hematol, Villejuif, France
[9] Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, Italy
[10] Celgene, Summit, NJ USA
[11] Bristol Myers Squibb, Summit, NJ USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.01.025
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
16O
引用
收藏
页码：S5 / S5
页数：1
相关论文
共 50 条
  • [31] R2: Preliminary Results of a Phase II Study of Lenalidomide and Rituximab in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (NHL)
    DeRook, Ian
    Odonnell, Robert T.
    Noble, B.
    Quirch, C.
    Tuscano, Joseph
    BLOOD, 2008, 112 (11) : 1052 - 1052
  • [32] R2: Preliminary Results of a Phase II Study of Lenalidomide and Rituximab in Relapsed Refractory Indolent Non-Hodgkin's Lymphoma (NHL).
    Dutia, Mrinal
    DeRoock, Ian
    Chee, Karen
    O'donnell, Robert
    Quirch, Christine
    Reed-Pease, Christine
    Tuscano, Joseph
    BLOOD, 2009, 114 (22) : 670 - 670
  • [33] Phase I and Pharmacokinetic (PK) Study of Everolimus (RAD001) in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL).
    Ogura, Michinori
    Uchida, Toshiki
    Maruyama, Dai
    Uike, Naokuni
    Choi, Ilseung
    Ishizawa, Kenichi
    Itoh, Kuniaki
    Ando, Kiyoshi
    Taniwaki, Masafumi
    Shimada, Naomi
    Kobayashi, Ken
    Tobinai, Kensei
    BLOOD, 2009, 114 (22) : 682 - 683
  • [34] Glofitamab in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): durable complete responses and manageable safety observed at clinically relevant doses in Phase I dose escalation
    Hutchings, M.
    Morschhauser, F.
    Iacoboni, G.
    Carlo-Stella, C.
    Offner, F. C.
    Sureda, A.
    Salles, G.
    Martinez-Lopez, J.
    Crump, M.
    Lundberg, L.
    Dixon, M.
    Kwan, A.
    Wei, M. C.
    Broeske, A-M E.
    Carlile, D.
    O'Hear, C.
    Dickinson, M. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 58 - 59
  • [35] A phase I study of inotuzumab ozogamicin (IO) in combination with temsirolimus (T) in patients (pts) with relapsed or refractory (R/R) CD22-positive (pos) B-cell non-Hodgkin lymphomas (NHL)
    Stathis, Anastasios
    Hitz, Felicitas
    Novak, Urban
    Bertoni, Francesco
    Terrot, Tatiana
    Moser, Laura
    Xenidou, Ioanna
    Mazzucchelli, Luca
    Ghielmini, Michele
    Sessa, Cristiana
    Zucca, Emanuele
    Cavalli, Franco
    CANCER RESEARCH, 2014, 74 (19)
  • [36] Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-hodgkin's lymphoma
    Prince, H. M.
    George, D.
    Patnaik, A.
    Mita, M.
    Dugan, M.
    Butterfoss, D.
    Masson, E.
    Culver, K. W.
    Burris, H. A., III
    Beck, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [37] A Phase I Trial of Nedd8-Activating Enzyme (NAE) Inhibitor, Pevonedistat (PEVO) in Combination with Ibrutinib in Patients with Relapsed/Refractory (R/R) Non- Hodgkin Lymphoma (NHL)
    Torka, Pallawi
    Kambhampati, Swetha
    Muir, Alexandra
    Orand, Kirsten
    Smith, Lynne
    Herrera, Alex F.
    Lewis, Lionel
    Hernandez-Ilizaliturri, Francisco J.
    Chen, Lu
    Danilov, Alexey V.
    BLOOD, 2021, 138
  • [38] Phase I study of the sphingomyelin/cholesterol liposome formulation of vinorelbine in subjects with advanced solid tumors or non-Hodgkin's lymphoma (NHL)
    Imperiale, S. M.
    Tolcher, A. W.
    Sarantopouios, J.
    Batist, G.
    Sankhala, K.
    Fontanilla-Gines, J.
    Lu, B.
    Deitcher, S. R.
    Bleker, W. F.
    ANNALS OF ONCOLOGY, 2008, 19 : 145 - 145
  • [39] A phase II study of Xcellerated T cells™ in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (NHL)
    Gribben, JG
    Bartlett, NL
    Stephenson, JJ
    Milder, MS
    Boccia, RV
    Redfern, C
    Mizuno, VM
    Berenson, RJ
    Frohlich, MW
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) : 76 - 76
  • [40] A phase II study of Xcellerated T Cells in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (NHL)
    Gribben, JG
    Stephenson, JJ
    Bartlett, NL
    Milder, MS
    Boccia, RV
    Redfern, C
    Mizuno, VM
    Hillson, J
    Berenson, RJ
    Frohlich, MW
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 168S - 168S
12345